Reckitt Benckiser fined $1.7m for misleading claims about Nurofen’s ‘pain specific’ relief

Reckitt Benckiser has been ordered to pay a $1.7m fine after being found guilty of misleading consumers with claims Nurofen could target specific pain.

Nurofen Specific Pain products landscapeThe fine is a victory for the Australian Competition and Consumer Commission (ACCC) and for ABC series The Checkout, which called out the misleading branding in a segment broadcast in 2013.

The ACCC launched the action in the Federal Court, which found in a December ruling that the active ingredient in the pain-specific products was no different to that found in standard Nurofen and ordered the products off the shelves.

The company marketed the products as targeting a number of different pains, including back pain, period pain, migraine pain and tension headache.

Subscribe to keep reading

Join Mumbrella Pro to access the Mumbrella archive and read our premium analysis of everything under the media and marketing umbrella.

Subscribe

Get the latest media and marketing industry news (and views) direct to your inbox.

Sign up to the free Mumbrella newsletter now.

"*" indicates required fields

 

SUBSCRIBE

Sign up to our free daily update to get the latest in media and marketing.